Experience with Linezolid for the Treatment of Rifampin-Susceptible Tuberculosis in San Francisco
Janice K. Louie, Gustavo E. Velásquez, Allison L. Phillips, John D. Szumowski
Open Forum Infectious Diseases · 2025-11
Abstract
Linezolid is recommended for the treatment of rifampin-resistant tuberculosis (TB), but its role in rifampin-susceptible TB (RS-TB) is less understood. In 45 RS-TB patients treated with linezolid, 8 stopped due to adverse events, most commonly cytopenias. Further research is needed on linezolid efficacy, dosing, and adverse event management in RS-TB.
MeSH terms
- Medicine
- Linezolid
- Adverse effect
- Tuberculosis
- Intensive care medicine
- Surgery
- Internal medicine
- Antibacterial agent